Results 61 to 70 of about 2,211 (199)

Preclinical models for evaluating psychedelics in the treatment of major depressive disorder

British Journal of Pharmacology, EarlyView.
Psychedelic drugs have seen a resurgence in interest as a next generation of psychiatric medicines with potential as rapid‐acting antidepressants (RAADs). Despite promising early clinical trials, the mechanisms which underlie the effects of psychedelics are poorly understood.
Laith Alexander, Dasha Anderson, Luke Baxter, Matthew Claydon, James Rucker, Emma S. J. Robinson   +5 more
wiley   +1 more source

Dataset: Effects of ketamine optical isomers, psilocybin, psilocin and norpsilocin on time estimation and cognition in rats

, 2021
Dataset for the paper: Effects of ketamine optical isomers, psilocybin, psilocin and norpsilocin on time estimation and cognition in ...
Adam Hogendorf (3896932), Natalia Malikowska-Racia (10875226), Joanna Golebiowska (6053081), Agnieszka Nikiforuk (420161), Ryszard Bugno (5727881), Piotr Popik (292215), Pawel Zajdel (1737517), Shaun Yon-Seng Khoo (459463)   +7 more
core   +1 more source

The Australia story: Current status and future challenges for the clinical applications of psychedelics

British Journal of Pharmacology, EarlyView.
Abstract The past decade has seen a huge increase in clinical research with psychedelic drugs and 3,4‐methylenedioxymethamphetamine (MDMA), which have revealed great potential for treating mental health conditions. Given this progress in research, as well as the current unmet clinical need of millions of patients, in 2023, the Australian Therapeutic ...
David J Nutt, Peter Hunt, Anne Katrin Schlag, Paul Fitzgerald   +3 more
wiley   +1 more source

Binding Interactions of Psilocin and Serotonin in the 5-HT2A Receptor

, 2020
Psilocin is a molecule found in psilocybin mushrooms, which are typically consumed recreationally for their hallucinogenic effects. Recently, studies have shown that psilocin can have almost immediate antidepressant effects in patients who are treatment ...
Lewis, Stephanie N., Barnes, Katie
core  

Image_1_Underlying pharmacological mechanisms of psilocin-induced broadband desynchronization and disconnection of EEG in rats.jpg

, 2023
IntroductionPsilocybin is one of the most extensively studied psychedelic drugs with a broad therapeutic potential. Despite the fact that its psychoactivity is mainly attributed to the agonism at 5-HT2A receptors, it has high binding affinity also to 5 ...
Tomáš Pálení ček (16415436), Martin Kuchař, Vlastimil Koudelka, Filip Tylš (16415421), Zdeňka Bendová (8980022), Tomáš Novák (11526703), Tomáš Pálení ček, Marcel Bochin, Jiří Horáček, Jiří Horáček (4305688), Václava Piorecká (16415427), Čestmír Vejmola, Lukáš Kadeřábek, Tomáš Novák, Martin Brunovský, Martin Kuchař (5557973), Václava Piorecká, Filip Tylš, Marcel Bochin (16415433), Martin Brunovský (9566726), Čestmír Vejmola (16415424), Vlastimil Koudelka (10029089), Zdeňka Bendová, Lukáš Kadeřábek (16415430)   +23 more
core   +1 more source

Psilocybin as a novel treatment for chronic pain

British Journal of Pharmacology, EarlyView.
Abstract Psychedelic drugs are under active consideration for clinical use and have generated significant interest for their potential as anti‐nociceptive treatments for chronic pain, and for addressing conditions like depression, frequently co‐morbid with pain.
Tate Askey, Reena Lasrado, Maria Maiarú, Gary J. Stephens   +3 more
wiley   +1 more source

Psilocybin modulation of time-varying functional connectivity is associated with plasma psilocin and subjective effects

, 2022
BACKGROUND: Psilocin, the neuroactive metabolite of psilocybin, is a serotonergic psychedelic that induces an acute altered state of consciousness, evokes lasting changes in mood and personality in healthy individuals, and has potential as an ...
Dea S. Stenbæk, Patrick M. Fisher, Gitte M. Knudsen, Melanie Ganz, Martin K. Madsen, Mørup, Morten, Ganz, Melanie, Anders Lykkebo-Valløe, Morten Mørup, Stenbæk, Dea S, Armand, Sophia, Fisher, Patrick M, Ozenne, Brice, Anders S. Olsen, Sophia Armand, Olsen, Anders S, Madsen, Martin K, Knudsen, Gitte M, Lykkebo-Valløe, Anders, Brice Ozenne   +19 more
core   +1 more source

Neuropsychopharmacology of hallucinogenic and non‐hallucinogenic 5‐HT2A receptor agonists

British Journal of Pharmacology, EarlyView.
Psychedelic drugs such as LSD and psilocin were once relegated to the fringes of medical research because of their association with counterculture movements and a perceived concern about harm through recreational use, and their consequent legal prohibition in the early 1970s.
Trevor Sharp, Aurelija Ippolito
wiley   +1 more source

A Revised Model for Muscarine Biosynthesis Involving Lysine Trimethylation

Angewandte Chemie, Volume 138, Issue 24, 8 June 2026.
The fatal mushroom toxin l‐(+)‐muscarine is one of the most prominent natural products. We elucidated its biosynthetic origin in the sweating mushroom Collybia rivulosa based on incorporation of stable isotope‐labeled compounds and extensive mass spectrometric analyses.
Sebastian Dörner, Kai Rogge, Felix Trottmann, Christian Hertweck, Dirk Hoffmeister   +4 more
wiley   +2 more sources

Psychedelics, entactogens and psychoplastogens for depression and related disorders

British Journal of Pharmacology, EarlyView.
Currently, the most actively investigated rapidly acting antidepressants, anxiolytics and/or anti PTSD agents, include psychedelics e.g. psilocybin, LSD, N,N‐dimethyltryptamine, ayahuasca; non‐hallucinogenic entactogens, e.g. MDMA; psychoplastogens which rapidly promote neuroplasticity, e.g.
Daniel Hoyer
wiley   +1 more source